{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:01:39Z","timestamp":1790827299882,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K14669"],"award-info":[{"award-number":["23K14669"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s11060-024-04681-8","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T01:01:35Z","timestamp":1713747695000},"page":"415-423","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Impact of concurrent antibody\u2013drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: a multicenter retrospective study"],"prefix":"10.1007","volume":"168","author":[{"given":"Yutaro","family":"Koide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sou","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurika","family":"Shindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kodaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"key":"4681_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.adro.2019.07.012","volume":"5","author":"AB Barbour","year":"2020","unstructured":"Barbour AB, Jacobs CD, Williamson H et al (2020) Radiation Therapy Practice Patterns for Brain Metastases in the United States in the Stereotactic Radiosurgery Era. Adv Radiat Oncol 5:43\u201352. https:\/\/doi.org\/10.1016\/j.adro.2019.07.012","journal-title":"Adv Radiat Oncol"},{"key":"4681_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.prro.2022.02.003","volume":"12","author":"V Gondi","year":"2022","unstructured":"Gondi V, Bauman G, Bradfield L et al (2022) Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol 12:265\u2013282. https:\/\/doi.org\/10.1016\/j.prro.2022.02.003","journal-title":"Pract Radiat Oncol"},{"key":"4681_CR3","doi-asserted-by":"publisher","first-page":"101402","DOI":"10.1016\/j.adro.2023.101402","volume":"9","author":"C Ladbury","year":"2024","unstructured":"Ladbury C, Pennock M, Yilmaz T et al (2024) Stereotactic Radiosurgery in the Management of Brain Metastases: A Case-Based Radiosurgery Society Practice Guideline. Adv Radiat Oncol 9:101402. https:\/\/doi.org\/10.1016\/j.adro.2023.101402","journal-title":"Adv Radiat Oncol"},{"key":"4681_CR4","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy RK, Loi S, Okines A et al (2020) Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med 382:597\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa1914609","journal-title":"N Engl J Med"},{"key":"4681_CR5","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1200\/JCO.20.00775","volume":"38","author":"NU Lin","year":"2020","unstructured":"Lin NU, Borges V, Anders C et al (2020) Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. J Clin Oncol 38:2610\u20132619. https:\/\/doi.org\/10.1200\/JCO.20.00775","journal-title":"J Clin Oncol"},{"key":"4681_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","volume":"9","author":"NU Lin","year":"2023","unstructured":"Lin NU, Murthy RK, Abramson V et al (2023) Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. JAMA Oncol 9:197\u2013205. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5610","journal-title":"JAMA Oncol"},{"key":"4681_CR7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T et al (2020) Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 382:610\u2013621. https:\/\/doi.org\/10.1056\/NEJMoa1914510","journal-title":"N Engl J Med"},{"key":"4681_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Hegg R, Chung W-P et al (2023) Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 401:105\u2013117. https:\/\/doi.org\/10.1016\/S0140-6736(22)02420-5","journal-title":"Lancet"},{"key":"4681_CR9","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.22.00520","volume":"40","author":"N Ramakrishna","year":"2022","unstructured":"Ramakrishna N, Anders CK, Lin NU et al (2022) Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. J Clin Oncol 40:2636\u20132655. https:\/\/doi.org\/10.1200\/JCO.22.00520","journal-title":"J Clin Oncol"},{"key":"4681_CR10","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.21.02314","volume":"40","author":"MA Vogelbaum","year":"2022","unstructured":"Vogelbaum MA, Brown PD, Messersmith H et al (2022) Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol 40:492\u2013516. https:\/\/doi.org\/10.1200\/JCO.21.02314","journal-title":"J Clin Oncol"},{"key":"4681_CR11","doi-asserted-by":"publisher","first-page":"102233","DOI":"10.1016\/j.esmoop.2024.102233","volume":"9","author":"I Michelon","year":"2024","unstructured":"Michelon I, Vilbert M, Marinho AD et al (2024) Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis. ESMO Open 9:102233. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102233","journal-title":"ESMO Open"},{"key":"4681_CR12","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jamaoncol.2023.4492","volume":"9","author":"ES Lebow","year":"2023","unstructured":"Lebow ES, Pike LRG, Seidman AD et al (2023) Symptomatic Necrosis With Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain Metastases. JAMA Oncol 9:1729\u20131733. https:\/\/doi.org\/10.1001\/jamaoncol.2023.4492","journal-title":"JAMA Oncol"},{"key":"4681_CR13","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.3390\/cancers13153682","volume":"13","author":"R Tonse","year":"2021","unstructured":"Tonse R, Tom MC, Mehta MP et al (2021) Integration of Systemic Therapy and Stereotactic Radiosurgery for Brain Metastases. Cancers 13:3682. https:\/\/doi.org\/10.3390\/cancers13153682","journal-title":"Cancers"},{"key":"4681_CR14","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","volume":"16","author":"NU Lin","year":"2015","unstructured":"Lin NU, Lee EQ, Aoyama H et al (2015) Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 16:e270\u2013e278. https:\/\/doi.org\/10.1016\/S1470-2045(15)70057-4","journal-title":"Lancet Oncol"},{"key":"4681_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ijrobp.2023.07.015","volume":"118","author":"B Vellayappan","year":"2024","unstructured":"Vellayappan B, Lim-Fat MJ, Kotecha R et al (2024) A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and International Stereotactic Radiosurgery Society Recommendations. Int J Radiat Oncol Biol Phys 118:14\u201328. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.07.015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4681_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s11060-017-2442-8","volume":"133","author":"JM Kim","year":"2017","unstructured":"Kim JM, Miller JA, Kotecha R et al (2017) The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies. J Neurooncol 133:357\u2013368. https:\/\/doi.org\/10.1007\/s11060-017-2442-8","journal-title":"J Neurooncol"},{"key":"4681_CR17","doi-asserted-by":"publisher","first-page":"109920","DOI":"10.1016\/j.radonc.2023.109920","volume":"189","author":"J Hall","year":"2023","unstructured":"Hall J, Lui K, Tan X et al (2023) Factors associated with radiation necrosis and intracranial control in patients treated with immune checkpoint inhibitors and stereotactic radiotherapy. Radiother Oncol 189:109920. https:\/\/doi.org\/10.1016\/j.radonc.2023.109920","journal-title":"Radiother Oncol"},{"key":"4681_CR18","doi-asserted-by":"publisher","unstructured":"Salvestrini V, Kim K, Caini S, et al (2023) Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: a systematic review and meta-analysis. Radiother Oncol 186:109805. https:\/\/doi.org\/10.1016\/j.radonc.2023.109805","DOI":"10.1016\/j.radonc.2023.109805"},{"key":"4681_CR19","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/S1470-2045(23)00534-X","volume":"25","author":"I Meattini","year":"2024","unstructured":"Meattini I, Becherini C, Caini S et al (2024) International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations. Lancet Oncol 25:e73\u2013e83. https:\/\/doi.org\/10.1016\/S1470-2045(23)00534-X","journal-title":"Lancet Oncol"},{"key":"4681_CR20","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3390\/cancers14061514","volume":"14","author":"E Ippolito","year":"2022","unstructured":"Ippolito E, Silipigni S, Matteucci P et al (2022) Radiotherapy for HER 2 Positive Brain Metastases: Urgent Need for a Paradigm Shift. Cancers 14:1514. https:\/\/doi.org\/10.3390\/cancers14061514","journal-title":"Cancers"},{"key":"4681_CR21","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3390\/cancers15082278","volume":"15","author":"K Debbi","year":"2023","unstructured":"Debbi K, Grellier N, Loganadane G et al (2023) Interaction between Radiation Therapy and Targeted Therapies in HER2-Positive Breast Cancer: Literature Review, Levels of Evidence for Safety and Recommendations for Optimal Treatment Sequence. Cancers 15:2278. https:\/\/doi.org\/10.3390\/cancers15082278","journal-title":"Cancers"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04681-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04681-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04681-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T14:04:50Z","timestamp":1718805890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04681-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["4681"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04681-8","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,22]]},"assertion":[{"value":"26 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YK has a speaker\u2019s bureau for Hitachi Co., Global Breast Cancer Conference (GBCC), and received research funding from Japan Society for the Promotion of Science (JSPS, Grant Number 23K14669). MK has a research grant from Accuray Co. and speaker\u2019s bureau for Accuray Co., Chugai Pharmaceutical, and leadership\/fiduciary roles in Japanese Society for Radiation Oncology (educational committee, public relations committee, international committee), Japanese Breast cancer society (educational committee, guideline committee), and Japan Radiological Society (international committee, diversity committee). TK has a speaker\u2019s bureau for Hitachi Co., Bristol Myers Squibb., Accuray Co., Elekta Co., Ono Pharmaceutical Co., AstraZeneca Co., Taiho Pharmaceutical Co., Canon Co., and Janssen Pharmaceutical Co.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}